2014
Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents
Connor DF, Arnsten A, Pearson GS, Greco GF. Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents. Expert Opinion On Pharmacotherapy 2014, 15: 1601-1610. PMID: 24992513, DOI: 10.1517/14656566.2014.930437.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnimalsAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsChildDelayed-Action PreparationsGuanfacineHumansRandomized Controlled Trials as TopicTreatment OutcomeConceptsAttention-deficit/hyperactivity disorderHyperactivity disorderSymptoms of ADHDEvidence-based treatmentsTraumatic stressBehavioral dysregulationADHD studiesSmall effect sizesPrefrontal cortexAdolescents 6Behavioral conditionsAdolescentsEffect sizeGXRPsycINFO databasesGuanfacinePsychostimulantsShire PharmaceuticalsOpen trialChildrenPotential promiseSecond-line treatmentDisordersAntihypertensive agentsAdrenoreceptor agonist
2010
The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder
Arnsten A. The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Review Of Neurotherapeutics 2010, 10: 1595-1605. PMID: 20925474, PMCID: PMC3143019, DOI: 10.1586/ern.10.133.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic alpha-2 Receptor AgonistsAttentionAttention Deficit Disorder with HyperactivityBehaviorCatecholaminesEmotionsHumansPrefrontal CortexReceptors, Adrenergic, alpha-2ConceptsAttention-deficit/hyperactivity disorderPrefrontal cortexHyperactivity disorderPFC functionPFC gray matterPFC pyramidal cellsPyramidal cell networksDorsolateral prefrontal cortexPFC connectionsReceptors inhibitsPyramidal cellsAdrenergic agonistsDendritic spinesVentromedial prefrontal cortexGray matterRelated disordersBrain regionsNeuropsychiatric disordersPotassium channelsDisordersPatientsRecent dataPhysiological connectionTreatmentExecutive functioning
2000
Genetics of Childhood Disorders: XVIII. ADHD, Part 2: Norepinephrine Has a Critical Modulatory Influence on Prefrontal Cortical Function
ARNSTEN A, Lombroso P. Genetics of Childhood Disorders: XVIII. ADHD, Part 2: Norepinephrine Has a Critical Modulatory Influence on Prefrontal Cortical Function. Journal Of The American Academy Of Child & Adolescent Psychiatry 2000, 39: 1201-1203. PMID: 10986819, DOI: 10.1097/00004583-200009000-00022.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic alpha-AgonistsAnimalsAttention Deficit Disorder with HyperactivityCerebrovascular CirculationChildCognitionFemaleGenetic Predisposition to DiseaseHumansMaleNorepinephrinePrefrontal CortexReceptors, Adrenergic, alpha-1Receptors, Adrenergic, alpha-2
1999
Development of the Cerebral Cortex: XIV. Stress Impairs Prefrontal Cortical Function
Lombroso P, ARNSTEN A. Development of the Cerebral Cortex: XIV. Stress Impairs Prefrontal Cortical Function. Journal Of The American Academy Of Child & Adolescent Psychiatry 1999, 38: 220-222. PMID: 9951224, DOI: 10.1097/00004583-199902000-00024.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAdjustment DisordersAntipsychotic AgentsAttention Deficit Disorder with HyperactivityChildHumansInternetMaleNerve NetNeurobehavioral ManifestationsPrefrontal CortexStress, Psychological
1995
Guanfacine Treatment of Comorbid Attention-Deficit Hyperactivity Disorder and Tourette's Syndrome: Preliminary Clinical Experience
CHAPPELL P, RIDDLE M, SCAHILL L, LYNCH K, SCHULTZ R, ARNSTEN A, LECKMAN J, COHEN D. Guanfacine Treatment of Comorbid Attention-Deficit Hyperactivity Disorder and Tourette's Syndrome: Preliminary Clinical Experience. Journal Of The American Academy Of Child & Adolescent Psychiatry 1995, 34: 1140-1146. PMID: 7559307, DOI: 10.1097/00004583-199509000-00010.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic AgonistsAttention Deficit Disorder with HyperactivityChildFemaleFollow-Up StudiesGuanfacineHumansMalePsychological TestsTourette SyndromeTreatment OutcomeConceptsYale Global Tic Severity ScaleAttention deficit hyperactivity disorderTourette syndromeContinuous Performance TestHyperactivity disorderOpen-label studyCommon side effectsSeverity of motorComorbid attention deficit hyperactivity disorderSafe alternative therapySignificant decreaseTic Severity ScalePreliminary clinical experienceMajority of subjectsConners' Parent Rating ScaleTransient sedationControlled TrialsAlternative therapiesSedative effectsGuanfacine treatmentPhonic ticsSeverity ScaleSide effectsStimulant medicationTic severityAn Open Trial of Guanfacine in the Treatment of Attention-Deficit Hyperactivity Disorder
Hunt R, Arnsten A, Asbell M. An Open Trial of Guanfacine in the Treatment of Attention-Deficit Hyperactivity Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 1995, 34: 50-54. PMID: 7860456, DOI: 10.1097/00004583-199501000-00013.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAttention Deficit Disorder with HyperactivityChildChild, PreschoolFemaleGuanfacineHumansMalePsychiatric Status Rating ScalesTreatment OutcomeConceptsAttention deficit hyperactivity disorderGreater attentional abilityConners' Parent RatingUse of guanfacineAttentional abilitiesConners' hyperactivityParent ratingsHyperactivity disorderFrustration tolerancePatients' mean scoresSelective binding profileHyperactive childrenLonger excretionGuanfacine treatmentADHDHyperactive behaviorMean scoreSide effectsAlpha-2 noradrenergic agonistPsychiatric outpatientsGuanfacineDouble-blind studyBehavioral changesSedative side effectsOpen trial